Novo Nordisk aims to submit hemophilia drug for approval this year

Phase III results have confirmed Novo Nordisk’s faith in concizumab, which treats hemophilia A and B, and the company is now expecting to submit the drug for regulatory approval in H2 2022.

One of Novo's potential hemophilia drugs has demonstrated the desired effects in a phase III trial, dubbed Explorer 7

Before the year is over, Novo Nordisk will have submitted hemophilia drug concizumab for review by regulatory authorities, the company reports in its first quarterly report for 2022 on Friday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs